Besivance and Vitreous floaters - a phase IV clinical study of FDA data

Summary:

Vitreous floaters is reported as a side effect among people who take Besivance (besifloxacin hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lucentis, and have Diabetic retinopathy.

The phase IV clinical study analyzes which people have Vitreous floaters when taking Besivance. It is created by eHealthMe based on reports of 1,097 people who have side effects when taking Besivance from the FDA, and is updated regularly.

What is Besivance?

Besivance has active ingredients of besifloxacin hydrochloride. eHealthMe is studying from 1,102 Besivance users. Check the latest studies of Besivance.

What is Vitreous floaters?

Vitreous floaters (spots before the eyes) is found to be associated with 834 drugs and 838 conditions by eHealthMe. Check the latest studies of Vitreous floaters.

On Jul, 20, 2026

1,097 people reported to have side effects when taking Besivance.
Among them, 11 people (1.0%) have Vitreous floaters.

Could Besivance cause Vitreous floaters?

Among these 11 people:

How long have people been on Besivance when they have Vitreous floaters? *

What is the gender of people who have Vitreous floaters when taking Besivance? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Vitreous floaters when taking Besivance? *

What are other drugs people take besides Besivance? *

What are other side effects people have besides Vitreous floaters? *

Visual Acuity Reduced (reduced clearness of vision): 3 people, 27.27%
Ocular Discomfort (a generic expression when there is lack of ease in/about the eyes): 2 people, 18.18%
Vitreous Haemorrhage (intraocular (inside the eye) bleeding): 2 people, 18.18%
Confusional State: 2 people, 18.18%
Cystoid Macular Oedema (fluid accumulation after cataract surgery): 2 people, 18.18%
Dry Eyes (lack of adequate tears): 2 people, 18.18%
Endophthalmitis (inflammation of the internal coats of the eye): 2 people, 18.18%
Eye Pruritus (eye itching): 2 people, 18.18%
Foreign Body Sensation In Eyes (feeling of something in eye): 2 people, 18.18%
Lacrimation Increased: 2 people, 18.18%

What are the existing conditions these people have? *

Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 6 people, 54.55%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 4 people, 36.36%
Diabetic Eye Disease: 2 people, 18.18%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 2 people, 18.18%
Retinal Neovascularisation (development of tiny, abnormal, leaky blood vessels inside the retina): 1 person, 9.09%
Retinal Degeneration (death of the cells of the retina): 1 person, 9.09%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Besivance and have Vitreous floaters?

- Check whether Vitreous floaters is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Besivance:

Besivance (1,102 reports)

Browse all side effects of Besivance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitreous floaters:

Vitreous floaters (834 drugs)

Browse all the conditions that are associated with Vitreous floaters:

Vitreous floaters (838 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on besifloxacin hydrochloride (the active ingredients of Besivance) and Besivance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.